IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trialBrian I. Rini, Tim Eisen, Arnulf Stenzl et al.|The Lancet Oncology|2016Cited by 218
Rapid and Sustained Influence of Intravenous Zoledronic Acid on Course of Pain and Analgesics Consumption in Patients with Cancer with Bone Metastases: A Multicenter Open-Label Study Over 1 YearAlbrecht Kretzschmar, Gerhard Ehninger, Manfred Kindler et al.|Supportive Cancer Therapy|2007Cited by 19